Johnson & Johnson reported worldwide sales of $320 million for RYBREVANT® and LAZCLUZE® (lazertinib) in Q3 2026, representing 62.3% year-on-year growth. The combined products generated

Yuhan Corporation presented population PK/PD modeling results for YH35995 at the American Conference on Pharmacometrics (ACoP 2026) on October 12, 2026. YH35995 is a novel

Yuhan and Oscotec were jointly awarded the “Best Pharmaceutical Product” for lazertinib (LECLAZA®/LAZCLUZE™) at the inaugural Prix Galien Korea Awards, held on September 10, 2026, at The Shilla Seoul.

BlackRock, the world’s largest asset manager, has increased its equity stake in Yuhan for the second consecutive month. According to the industry, BlackRock Fund Advisors,

Yuhan Corporation announced that it will receive a $30 million milestone payment from Johnson & Johnson following the European commercial launch of lazertinib (Korean brand

Yuhan Corporation announced that it will receive a milestone payment of USD 45 million (approximately KRW 69 billion) from Janssen Biotech following the commercial launch